Are you Satoko Iwaki?

Claim your profile

Publications (2)2.3 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: There have been many reports indicating that the down-regulation of p21(WAF1/CIP1) is related to carcinogenesis and the development of various tumors; nevertheless, its association with epithelial ovarian cancer (EOC) remains controversial. In this study, we focused on serous ovarian cancer, which is the most prevalent histological type, and performed immunohistochemical analysis to examine the expression of p21(WAF1/CIP1) and p53 in 43 cases of serous-type EOC sourced from a single University Hospital: 14 stage I, 4 stage II, 21 stage III, and 4 stage IV. Positive p21(WAF1/CIP1) was found in 24 of 43 cases (56%), and positive p53 was detected in 21 of 43 cases (49%). Among stage III/IV cases, positive p21(WAF1/CIP1) staining was found in 11 of 25 cases (44%), and positive p53 staining was detected in 13 of 25 cases (52%). Univariate survival analysis for the entire cohort revealed that positive p21(WAF1/CIP1) was associated with a survival benefit. The 10-year survival rates of p21(WAF1/CIP1)-positive staining and p21(WAF1/CIP1)-negative staining were 82.4 and 39.5%, respectively, and there was a significant difference between the two groups (p<0.01). Overall survival for p21(WAF1/CIP1)-positive with p53-negative staining [p21(+)/p53(-)] was significantly different from p21(WAF1/CIP1)-positive with p53-positive [p21(+)/p53(+)], p21(WAF1/CIP1)-negative with p53-positive staining [p21(-)/p53(+)], and p21(WAF1/CIP1)-negative with p53-negative staining [p21(-)/p53(-)] (p<0.05). When only III/IV cases were evaluated, overall survival for [p21(+)/p53(-)] was significantly different from [p21(+)/p53(+)], [p21(-)/p53(+)], and [p21(-)/p53(-)] (p<0.05). These results suggested that the overexpression of p21(WAF1/CIP1) in conjunction with the loss of p53 expression was a stronger predictor of survival benefit than either molecule alone in Japanese serous-type advanced ovarian cancers with more than 10-year follow-up.
    No preview · Article · Sep 2005 · Oncology Reports
  • [Show abstract] [Hide abstract]
    ABSTRACT: An investigation into the effect of orally disintegrating antiemetic tablets (ramosetron OD 0.1 mg) on 16 outpatients undergoing chemotherapy for recurrent gynecologic malignancies was carried out using a questionnaire to evaluate their quality of life (QOL). The patients were divided into 2 groups: a control group in which the patients received only an intravenous drip infusion of 0.3 mg of ramosetron on the day of their chemotherapy and a double antiemetic therapy group in which the patients were treated with orally disintegrating antiemetic tablets for 4 days in addition to the intravenous drip. When outpatient chemotherapy (paclitaxel 80 mg/m2/1 h div + CBDCA AUC 2/1 h div) was performed, a comparison was made between the 2 groups, based on the results of a QOL questionnaire for antiemetic therapy during cancer chemotherapy (Ishihara's QOL survey method). This study found a greater improvement in QOL in the double antiemetic therapy group on days 2 to 4, a period when deterioration in QOL is usually observed. These findings suggest that orally disintegrating antiemetic tablets as a measure to reduce delayed nausea and vomiting are useful for improving QOL.
    No preview · Article · Oct 2003 · Gan to kagaku ryoho. Cancer & chemotherapy